Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Wilkinson

Showing results (311-320 of 319) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 319 results.
British Journal of Pharmacology|August 24, 2012
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritisR R Minter, E S Cohen, B Wang, et al.
JAMA Network Open|August 8, 2025
A Digital Therapeutic Intervention for Inpatients With Elevated Suicide Risk: A Randomized Clinical TrialCraig J Bryan, Patricia Simon, Samuel T Wilkinson, et al.
Molecular Psychiatry|October 5, 2018
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Molecular Psychiatry|January 9, 2019
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Journal of Cardiac Failure|June 24, 2021
The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT TrialFouad Chouairi, Michael A Fuery, Clancy W Mullan, et al.
JAMA Network Open|June 25, 2024
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical TrialManish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, et al.
The Journal of Clinical Psychiatry|April 22, 2020
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)Ewa Wajs, Leah Aluisio, Richard Holder, et al.
The New England Journal of Medicine|May 24, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionAmit Anand, Sanjay J Mathew, Gerard Sanacora, et al.
Molecular Psychiatry|September 7, 2022
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderatorsRebecca B Price, Nicholas Kissel, Andrew Baumeister, et al.
Pageof 32

Showing results (311-320 of 319) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 319 results.
British Journal of Pharmacology|August 24, 2012
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritisR R Minter, E S Cohen, B Wang, et al.
JAMA Network Open|August 8, 2025
A Digital Therapeutic Intervention for Inpatients With Elevated Suicide Risk: A Randomized Clinical TrialCraig J Bryan, Patricia Simon, Samuel T Wilkinson, et al.
Molecular Psychiatry|October 5, 2018
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Molecular Psychiatry|January 9, 2019
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)Maurizio Fava, Marlene P Freeman, Martina Flynn, et al.
Journal of Cardiac Failure|June 24, 2021
The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT TrialFouad Chouairi, Michael A Fuery, Clancy W Mullan, et al.
JAMA Network Open|June 25, 2024
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical TrialManish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, et al.
The Journal of Clinical Psychiatry|April 22, 2020
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)Ewa Wajs, Leah Aluisio, Richard Holder, et al.
The New England Journal of Medicine|May 24, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionAmit Anand, Sanjay J Mathew, Gerard Sanacora, et al.
Molecular Psychiatry|September 7, 2022
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderatorsRebecca B Price, Nicholas Kissel, Andrew Baumeister, et al.
Pageof 32